BCRX FY 2016 Earnings — BioCryst Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

BCRXBioCryst Pharmaceuticals, Inc.

$2B

FY 2016 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$26M-45.4% YoY

Gross Profit

$24M89.8% margin

Operating Income

-$49M-184.4% margin

Net Income

-$55M-209.3% margin

EPS (Diluted)

$-0.75

Cash Flow

Operating Cash Flow

-$53M

Free Cash Flow

-$59M

Stock-Based Comp.

$8M

Balance Sheet

Total Assets

$90M

Total Liabilities

$88M

Stockholders' Equity

-$566M

Cash & Equivalents

$22M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$26M	$48M	-45.4%
Gross Profit	$24M	$46M	-49.0%
Operating Income	-$49M	-$39M	-23.2%
Net Income	-$55M	-$43M	-28.2%